Investor protection firm Kaskela Law is investigating Select Medical Holdings Corp. (“Select Medical”) (NYSE: SEM) on behalf of the company’s shareholders to determine whether the recently announced proposed buyout of SEM shareholders is fair and provides investors with sufficient monetary consideration for their shares.

Click here for additional information: https://kaskelalaw.com/case/select-medical/

On March 2, 2026, Select Medical announced that it had agreed to be acquired by an investment consortium at a price of $16.50 per share in cash. Upon completion of the proposed transaction, Select Medical’s shareholders will be cashed out of their investment position and the company’s shares will no longer be publicly traded.

Our investigation has discovered that the transaction appears to have significant conflicts of interest, thus making the sales process and proposed $16.50 per share price unfair to Select Medical shareholders. Notably, at the time the buyout was announced, at least one stock analyst was maintaining a price target for Select Medical’s shares of $19.00 per share.

Select Medical shareholders who feel that the buyout price is too low are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by email at abell@kaskelalaw.com, to receive important information about their time-sensitive legal rights and options. Investors may also request additional information about this matter by clicking on the following link (or by copying and pasting the link into your browser):

https://kaskelalaw.com/case/select-medical/

ABOUT KASKELA LAW:

Kaskela Law exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent-fee basis. For additional information about the firm, including the firm’s recent monetary recoveries for investors in mergers & acquisition litigation, please visit our website (www.kaskelalaw.com) or contact us today at (888) 715 – 1740.

This communication may constitute attorney advertising in certain jurisdictions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260507831442/en/

"The investigation has discovered that the transaction appears to have significant conflicts of interest, thus making the sales process and proposed $16.50 per share price unfair to Select Medical shareholders."